# US 2021/0274759 A1 · A rodent model of b4galt1-mediated functions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0274759 A1
- Document ID: US20210274759A1
- Status: Published application
- Kind: A1
- Application number: 17/190,650
- Filed: 2021-03-03
- Published: 2021-09-09
- Earliest claimed: 2020-03-04
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Giusy Della Gatta; Qing Fang; Alan Shuldiner
- Web page: https://patentgrep.com/patent/US20210274759A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C12N 9/1048: {Glycosyltransferases (2.4)}
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- G01N 33/5088: {of vertebrates}
- A01K 2207/05: Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
- A01K 2207/15: Humanized animals
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure relates to genetically modified animals. More specifically, this disclosure relates to rodent animals in which an endogenous B4galt1 gene has been modified, e.g., to introduce a mutation that encodes an Asn to Ser substitution in the encoded B4galt1 protein at a position corresponding to position 352 in a human B4GALT1 protein, or to introduce a loss of function mutation (e.g., in a select tissue such as the liver). This disclosure also relates to use of such rodent animals in elucidating the role of B4galt1 in lipid metabolism.

## Claims

### Claim 1

A rodent, comprising a modification in an endogenous rodent p4 galactotransferase 1 (B4galt1) gene at an endogenous rodent B4galt1 locus.

### Claim 2 (depends on 1)

The rodent of claim 1, wherein the modification results in a modified rodent B4galt1 gene which encodes a B4galt1 protein comprising a substitution of Asn to Ser at an amino acid position corresponding to position 352 in a human B4GALT1 protein.

### Claim 3 (depends on 2)

The rodent of claim 2, wherein the rodent is a mouse, and the substitution is at amino acid position 353 of a mouse B4galt1 protein.

### Claim 4 (depends on 2)

The rodent of claim 2, wherein the rodent displays a decreased level of LDL-C, as compared to a wild type rodent without the modification.

### Claim 5 (depends on 1)

The rodent of claim 1, wherein the modification is in the genome of the rodent.

### Claim 6 (depends on 2)

The rodent of claim 2, wherein the rodent is homozygous for the modification.

### Claim 7 (depends on 1)

The rodent of claim 1, wherein the modification is a loss of function mutation.

### Claim 8 (depends on 7)

The rodent of claim 7, wherein the loss of function mutation comprises an insertion, deletion or substitution of one or more nucleotides resulting in a deletion, in whole or in part, of the coding sequence of the endogenous rodent B4galt1 gene.

### Claim 9 (depends on 8)

The rodent of claim 8, wherein the insertion, deletion or substitution of one or more nucleotides occurs in exon 2 of the endogenous rodent B4galt1 gene.

### Claim 10 (depends on 7)

The rodent of claim 7, wherein the modification is in the genome of the rodent.

### Claim 11 (depends on 7)

The rodent of claim 7, wherein the modification is introduced to the endogenous rodent B4galt1 gene in a target tissue or organ of the rodent.

### Claim 12 (depends on 11)

The rodent of claim 11, wherein the modification is introduced to the endogenous rodent B4galt1 gene in the liver of the rodent.

### Claim 13 (depends on 1)

The rodent of claim 1, wherein the rodent is a mouse or a rat.

### Claim 14

An isolated rodent cell or tissue, comprising a modification in an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus.

### Claim at position 15

-21. (canceled)

### Claim 22 (depends on 14)

The isolated rodent cell or tissue of claim 14, wherein the rodent cell is a rodent embryonic stem (ES) cell.

### Claim 23 (depends on 22)

A rodent embryo, comprising the isolated rodent cell of claim 22.

### Claim 24

A method of making a genetically modified rodent, comprising
(i) introducing a modification into an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus of a rodent embryonic stem (ES) cell, thereby obtaining a modified rodent ES cell comprising a modified rodent B4galt1 gene; and
(ii) making the genetically modified rodent using the modified rodent ES cell.

### Claim at position 19

-33. (canceled)

### Claim 34

A method of making a genetically modified rodent, comprising introducing a modification into an endogenous rodent B4galt1 gene at an endogenous rodent B4galt1 locus in a rodent tissue, thereby obtaining the genetically modified rodent.

### Claim at position 21

-41. (canceled)

### Claim 42 (depends on 34)

The method of claim 34, wherein the modification is introduced into the endogenous rodent B4galt1 gene through a CRISPR/Cas9 system comprising a guide RNA and a Cas9 enzyme, and wherein the guide RNA is delivered into the rodent by an AAV system.

### Claim 43 (depends on 42)

The method of claim 42, wherein the AAV system targets delivery of the guide RNA into the liver of the rodent.

### Claim at position 24

-46. (canceled)
